DiaCarta Inc (DiaCarta) is a developer of molecular diagnostics products for cancer and infectious diseases. The company offers genomic testing for biomarkers and provides clinical sample testing services in their CLIA-certified lab. It offers products such as gene mutation detection kits, colon cancer tests, fusion gene detection tests, adapter dimer removal, DNA sample card, CRISPR gene editing, PCR ready lysis buffers and genotyping tests, among others. DiaCarta provides services including CLIA lab services; NGS target sequencing, next generation sequencing, companion diagnostics and CAR-T immunotherapy. The company markets its products through a channel of network distributors. It serves in Germany, Egypt, Iran, Turkey, Iraq, and Costa Rica. DiaCarta is headquartered in Pleasanton, California, The US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company DiaCarta Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
DiaCarta Inc Company Overview
DiaCarta Inc Company Snapshot
DiaCarta Inc Pipeline Products and Ongoing Clinical Trials Overview
DiaCarta Inc – Pipeline Analysis Overview
DiaCarta Inc - Key Facts
DiaCarta Inc - Major Products and Services
DiaCarta Inc Pipeline Products by Development Stage
DiaCarta Inc Ongoing Clinical Trials by Trial Status
DiaCarta Inc Pipeline Products Overview
Companion Diagnostic Test - Cancer
Companion Diagnostic Test - Cancer Product Overview
Next Generation HPV Genotyping E6/E7 mRNA Test
Next Generation HPV Genotyping E6/E7 mRNA Test Product Overview
QuantiVirus Anti-SARS-CoV-2 IgG Test
QuantiVirus Anti-SARS-CoV-2 IgG Test Product Overview
QuantiVirus SARS-CoV-2 & Flu A/B Test
QuantiVirus SARS-CoV-2 & Flu A/B Test Product Overview
Quantivirus SARS-CoV-2 Antigen Rapid Home Test Kit
Quantivirus SARS-CoV-2 Antigen Rapid Home Test Kit Product Overview
QuantiVirus SARS-CoV-2 Multiplex Test Kit
QuantiVirus SARS-CoV-2 Multiplex Test Kit Product Overview
QuantiVirus SARS-CoV-2 Variant Detection Test
QuantiVirus SARS-CoV-2 Variant Detection Test Product Overview
RadTox QuantiDNA
RadTox QuantiDNA Product Overview
RadTox QuantiDNA Clinical Trial
Rapid SARS-Cov-2 Variant Detection Test
Rapid SARS-Cov-2 Variant Detection Test Product Overview
TB Drug Resistance Mutation Test
TB Drug Resistance Mutation Test Product Overview
DiaCarta Inc - Key Competitors
DiaCarta Inc - Key Employees
DiaCarta Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
DiaCarta Inc, Recent Developments
Mar 11, 2024: Florida Selects DiaCarta's cfDNA Test (RadTox) for Statewide Use to Detect Early Response of Cancer Treatment
Dec 15, 2023: DiaCarta Obtains CLIA Approval For iCOLON iFOB Test
Jul 24, 2023: DiaCarta and HMC/HML Team up for Customizing Lab Development Test Validations and Compliances in the US Market
Apr 16, 2023: DiaCarta announces five abstracts accepted for presentation at AACR Annual Meeting 2023
Jan 13, 2023: US FDA grants EUA for DiaCarta’s QuantiVirus MPXV test
Jul 20, 2022: DiaCarta receives CE-IVD mark for its SARS CoV-2 Flu A/B combo test
Apr 07, 2022: DiaCarta Expands Board Leadership with Industry Veteran
Nov 30, 2021: DiaCarta's multivariant COVID-19 test accurately detects the Omicron variant
Oct 27, 2021: DiaCarta's ColoScape assay detects precancerous colorectal cancer lesions and colorectal cancer mutations with high sensitivity
Sep 09, 2021: DiaCarta receives CE/IVD for its new COVID 19 screening test that identifies delta plus and new variants
Table 18: Quantivirus SARS-CoV-2 Antigen Rapid Home Test Kit - Product Status
Table 19: Quantivirus SARS-CoV-2 Antigen Rapid Home Test Kit - Product Description
Table 20: QuantiVirus SARS-CoV-2 Multiplex Test Kit - Product Status
Table 21: QuantiVirus SARS-CoV-2 Multiplex Test Kit - Product Description
Table 22: QuantiVirus SARS-CoV-2 Variant Detection Test - Product Status
Table 23: QuantiVirus SARS-CoV-2 Variant Detection Test - Product Description
Table 24: RadTox QuantiDNA - Product Status
Table 25: RadTox QuantiDNA - Product Description
Table 26: RadTox QuantiDNA - Prospective Observational Exploratory Clinical Study to Determine the Assay Cut-off for the RadTox Test in Prostate Cancer Patients to Predict Gastrointestinal Radiation Toxicity Using Circulating Cell Free DNA Directly from Plasma
Table 27: Rapid SARS-Cov-2 Variant Detection Test - Product Status
Table 28: Rapid SARS-Cov-2 Variant Detection Test - Product Description
Table 29: TB Drug Resistance Mutation Test - Product Status
Table 30: TB Drug Resistance Mutation Test - Product Description
Table 31: DiaCarta Inc, Key Employees
Table 32: DiaCarta Inc, Other Locations
Table 33: Glossary
List of Figures
Figure 1: DiaCarta Inc Pipeline Products by Equipment Type
Figure 2: DiaCarta Inc Pipeline Products by Development Stage
Figure 3: DiaCarta Inc Ongoing Clinical Trials by Trial Status